Clinical trials: Neovascular Glaucoma
Glaucoma, Neovascular
Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied
The researchers in this trial want to learn how the drug aflibercept works in in Japanese patients with increased eye pressure that is caused by new blood vessels growing in the eye (neovascular glaucoma or NVG).
- Trial name
- VENERA (NCT03639675)
- Testing
- Aflibercept (EYLEA, BAY86-5321), Topical IOP-lowering drugs
- Where
- 7 sites in Japan
- Volunteers
- 16 people
- Sponsor
- Bayer
Choroidal Neovascularization, Macular Edema
An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.
The pupose of this study is to evaluate the safety and the efficacy of ranibizumab in rare VEGF driven ocular diseases.
- Conditions
- Choroidal Neovascularization, Macular Edema, Glaucoma, Neovascular, Diabetic Retinopathy
- Trial name
- ECLIPSE (NCT01908816)
- Testing
- ranibizumab
- Where
- 39 sites in France
- Volunteers
- 270 people
- Sponsor
- Novartis Pharmaceuticals
Ischaemic Central Retinal Vein Occlusion, Neovascular Glaucoma
Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG
A prospective, randomised, placebo-controlled, double-masked, three-armed multi-centre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma - the…
- Trial name
- STRONG (NCT02947867)
- Testing
- aganirsen
- Volunteers
- 333 people
- Sponsor
- Gene Signal SAS
Neovascular Glaucoma
Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)
This is a prospective, observational, multi-center and post-authorization safety study that includes patients with a diagnosis of Neovascular Glaucoma. The investigator will have made the decision to use Eylea for treatment.
- Trial name
- NCT04519619
- Testing
- Aflibercept (Eylea, BAY86-5321)
- Where
- Japan
- Volunteers
- 480 people
- Sponsor
- Bayer
Neovascular Age Related Macular Degeneration (AMD), Open Angle Glaucoma
TF (SENSIMED Triggerfish) in Intraocular Anti-VEGF (Vascular Endothelial Growth Factor) Injection
This is a prospective, open label study assessing the 24-hour IOP patterns using TF in patients undergoing anti-VEGF injection for the treatment of neovascular AMD (age related macular degeneration).
- Trial name
- NCT01983579
- Testing
- Intraocular anti-VEGF injection, SENSIMED Triggerfish
- Where
- Spain
- Volunteers
- 4 people
- Sponsor
- Sensimed AG
Open Angle Glaucoma, Angle Closure Glaucoma
Oculusgen (Ologen) Glaucoma MMC Control in Estonia
To compare the safety and effectiveness between ologen collagen matrix and mitomycin-C (MMC) in glaucoma surgery. The ologen collagen matrix implantation procedure is same as traditional trabeculectomy except implant the ologen…
- Conditions
- Open Angle Glaucoma, Angle Closure Glaucoma, Uveitis Glaucoma, Young Age Glaucoma
- Trial name
- NCT00524758
- Testing
- ologen (oculusgen) collagen matrix, MMC in Trabeculectomy
- Where
- Estonia
- Volunteers
- 20 people
- Sponsor
- Pro Top & Mediking Company Limited
Glaucoma, Neovascular
Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients
To assess the efficacy and safety of the administration of aflibercept by intravitreal injection in comparison to sham to control intraocular pressure in patients with neovascular glaucoma.
- Trial name
- VEGA (NCT02396316)
- Testing
- Aflibercept (Eylea, BAY 86-5321)
- Where
- 19 sites in Japan
- Volunteers
- 54 people
- Sponsor
- Bayer